Gene: Lpl (lipoprotein lipase)  Rattus norvegicus Symbol: Lpl Name: lipoprotein lipase Description: ENCODES a protein that exhibits lipoprotein lipase activity; triglyceride binding; apolipoprotein binding (ortholog); INVOLVED IN lipid catabolic process; response to cold; response to drug; PARTICIPATES IN lipid metabolic pathway; lipoprotein metabolic pathway; Alzheimer disease pathway; ASSOCIATED WITH Diabetes Mellitus, Experimental; Glomerulosclerosis, Focal Segmental; Hypertriglyceridemia; FOUND IN extracellular matrix; cell surface (ortholog); extracellular space (ortholog); INTERACTS WITH (R)-noradrenaline; 1-naphthyl isothiocyanate; 17alpha-ethynylestradiol Type: protein-coding RefSeq Status: PROVISIONAL Also known as: lipoprotein lipase; MGC93586 Orthologs: Homo sapiens : LPL (lipoprotein lipase)  HGNC Mus musculus : Lpl (lipoprotein lipase)  MGI Latest Assembly: RGSC Genome Assembly v3.4 Position: Map Chr Position Strand Source Rat Cytogenetic Map 16 p14   NCBI RGSC Genome Assembly v5.0 16 22,432,084 - 22,455,884 - NCBI RGSC Genome Assembly v3.4 16 22,533,105 - 22,556,905 - NCBI Rat Celera Assembly 16 20,988,473 - 21,012,282 - NCBI Genome Assembly 3.1 16 22,532,512 - 22,556,890 - NCBI RH 3.4 16 252.82   RGD Model Launch Genome Browser (GBrowse) Annotation    (Toggle Detail/Summary View) Disease Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) Coronary Artery Disease   ISS RGD:70836 1580537   RGD   Diabetes Mellitus, Experimental   IEP   2313303   RGD   Diabetes Mellitus, Type 2   ISS RGD:70836 2313298 DNA:SNP:intron:13836C>A (rs343) (human) RGD   Diabetes Mellitus, Type 2   ISS RGD:70836 2313304 associated with Obesity RGD   Diabetes Mellitus, Type 2   ISS RGD:70836 1580537   RGD   Diabetic Nephropathies Resistance ISS RGD:70836 2306755   RGD   Glomerulosclerosis, Focal Segmental   IEP   2308781   RGD   Hyperlipidemia, Familial Combined   ISS RGD:70836 7240710   OMIM   Hyperlipoproteinemia Type I   ISS   1302536   RGD   Hyperlipoproteinemia Type I   ISS RGD:70836 7240710   OMIM   Hyperlipoproteinemia Type I   ISS RGD:70836 1580533   RGD   Hypertension   ISS RGD:70836 1580535   RGD   Hypertriglyceridemia   IED   2313581   RGD   Hypertriglyceridemia   ISS RGD:70836 1580533   RGD   Hypertriglyceridemia Susceptibility ISS RGD:70836 2313305   RGD   Insulin Resistance   ISS RGD:10876 2313300   RGD   Kidney Failure, Chronic   IEP   6909179   RGD   Lipid Metabolism, Inborn Errors   ISS RGD:70836 7240710   OMIM   Muscular Diseases   ISS   1302535   RGD   Myocardial Infarction Susceptibility ISS RGD:70836 2313302 associated with Diabetes Mellitus, Non-Insulin-Dependent;DNA:SNP: :p.D9N (rs1801177) (human) RGD   Obesity   IEP   2313580 mRNA:increased expression:white fat RGD   Obesity   ISS RGD:10876 2313300   RGD   Gene-Chemical Interaction Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) (3S,5R)-fluvastatin multiple interactions ISO RGD:70836 6480464 [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; more ... CTD PMID:19773416 (R)-noradrenaline increases expression EXP   6480464 Norepinephrine results in increased expression of LPL mRNA CTD PMID:9032464 (R)-noradrenaline multiple interactions EXP   6480464 Prazosin inhibits the reaction [Norepinephrine results in increased expression of LPL mRNA]; more ... CTD PMID:9032464 (S)-nicotine increases expression ISO RGD:10876 6480464 Nicotine results in increased expression of LPL mRNA CTD PMID:21955143 1-naphthyl isothiocyanate increases expression EXP   6480464 1-Naphthylisothiocyanate results in increased expression of LPL mRNA CTD PMID:17522070 17alpha-ethynylestradiol affects expression ISO RGD:10876 6480464 Ethinyl Estradiol affects the expression of LPL mRNA CTD PMID:17555576 17alpha-ethynylestradiol decreases expression EXP   6480464 Ethinyl Estradiol results in decreased expression of LPL mRNA CTD PMID:17557909 17alpha-ethynylestradiol multiple interactions ISO RGD:10876 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of LPL mRNA CTD PMID:17942748 17alpha-ethynylestradiol decreases expression ISO RGD:10876 6480464 Ethinyl Estradiol results in decreased expression of LPL mRNA CTD PMID:17942748 17beta-estradiol multiple interactions ISO RGD:10876 6480464 ESR1 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]; more ... CTD PMID:17974624 17beta-estradiol multiple interactions ISO RGD:70836 6480464 [Estradiol binds to ESR2 protein] which results in increased expression of LPL mRNA CTD PMID:20404318 17beta-estradiol increases expression EXP   6480464 Estradiol results in increased expression of LPL mRNA CTD PMID:17522070 17beta-estradiol increases expression ISO RGD:10876 6480464 Estradiol results in increased expression of LPL mRNA CTD PMID:17974624 17beta-estradiol decreases expression ISO RGD:10876 6480464 Estradiol results in decreased expression of LPL mRNA CTD PMID:16643890 17beta-estradiol affects expression ISO RGD:70836 6480464 Estradiol affects the expression of LPL mRNA CTD PMID:14699072 17beta-hydroxy-5alpha-androstan-3-one increases expression ISO RGD:10876 6480464 Dihydrotestosterone results in increased expression of LPL mRNA CTD PMID:16990341 2,2',4,4',5,5'-hexachlorobiphenyl increases expression EXP   6480464 2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of LPL mRNA CTD PMID:20959002 2,2',5,5'-tetrachlorobiphenyl increases expression ISO RGD:70836 6480464 2,5,2',5'-tetrachlorobiphenyl results in increased expression of LPL mRNA CTD PMID:21703328 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:70836 6480464 Tetrachlorodibenzodioxin results in decreased expression of LPL mRNA CTD PMID:20106945 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP   6480464 Tetrachlorodibenzodioxin results in decreased expression of LPL mRNA CTD PMID:23238561 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:10876 6480464 Tetrachlorodibenzodioxin results in increased expression of LPL mRNA CTD PMID:15800033 more ... 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:10876 6480464 Tetrachlorodibenzodioxin results in increased expression of LPL mRNA CTD PMID:15800033 more ... 2,3,7,8-tetrachlorodibenzodioxine decreases activity ISO RGD:10876 6480464 Tetrachlorodibenzodioxin results in decreased activity of LPL protein CTD PMID:9414485 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:10876 6480464 AHR protein promotes the reaction [Tetrachlorodibenzodioxin results in decreased activity of LPL protein]; more ... CTD PMID:9414485 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP   6480464 Tetrachlorodibenzodioxin results in increased expression of LPL mRNA CTD PMID:20959002 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:10876 6480464 Tetrachlorodibenzodioxin affects the expression of LPL mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:10876 6480464 Tetrachlorodibenzodioxin results in increased expression of LPL mRNA CTD PMID:15800033 more ... 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:10876 6480464 Tetrachlorodibenzodioxin results in increased expression of LPL mRNA CTD PMID:18827440 more ... 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:10876 6480464 Tetrachlorodibenzodioxin results in decreased expression of LPL mRNA CTD PMID:17942748 PMID:7537747 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:10876 6480464 Tetrachlorodibenzodioxin results in increased expression of LPL mRNA CTD PMID:18827440 more ... 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:10876 6480464 Tetrachlorodibenzodioxin results in increased expression of LPL mRNA CTD PMID:16114106 more ... 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:10876 6480464 Tetrachlorodibenzodioxin results in increased expression of LPL mRNA CTD PMID:16114106 more ... 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:10876 6480464 Tetrachlorodibenzodioxin results in increased expression of LPL mRNA CTD PMID:15800033 more ... 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:10876 6480464 Tetrachlorodibenzodioxin results in decreased expression of LPL mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:10876 6480464 Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of LPL mRNA] CTD PMID:16054899 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:10876 6480464 AHR protein affects the reaction [Tetrachlorodibenzodioxin results in increased expression of LPL mRNA] CTD PMID:18827440 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:10876 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of LPL mRNA CTD PMID:17942748 2-butoxyethanol decreases expression ISO RGD:10876 6480464 n-butoxyethanol results in decreased expression of LPL mRNA CTD PMID:19812364 25-hydroxycholesterol decreases expression ISO RGD:70836 6480464 25-hydroxycholesterol results in decreased expression of LPL mRNA CTD PMID:8567968 25-hydroxycholesterol decreases activity ISO RGD:70836 6480464 25-hydroxycholesterol results in decreased activity of LPL protein CTD PMID:8567968 3,3',4,4',5-pentachlorobiphenyl increases expression EXP   6480464 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of LPL mRNA CTD PMID:20959002 3,3',5-triiodo-L-thyronine increases expression EXP   6480464 Triiodothyronine results in increased expression of LPL mRNA CTD PMID:15953391 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:70836 6480464 [rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LPL mRNA; more ... CTD PMID:20206132 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:10876 6480464 T 0070907 inhibits the reaction [[rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of LPL mRNA]; more ... CTD PMID:23086663 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:70836 6480464 [rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of LPL mRNA; more ... CTD PMID:23086663 3-isobutyl-1-methyl-7H-xanthine increases expression ISO RGD:70836 6480464 1-Methyl-3-isobutylxanthine results in increased expression of LPL mRNA CTD PMID:22645054 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:70836 6480464 aloe emodin inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased expression of LPL mRNA] CTD PMID:22645054 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:10876 6480464 bisphenol A inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPL mRNA]; more ... CTD PMID:22197818 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:70836 6480464 [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPL mRNA; more ... CTD PMID:19186324 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:10876 6480464 [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of LPL mRNA; more ... CTD PMID:16054899 7,12-dimethyltetraphene decreases expression EXP   6480464 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of LPL mRNA CTD PMID:12376462 7alpha-hydroxycholesterol decreases activity ISO RGD:70836 6480464 cholest-5-en-3 beta,7 alpha-diol results in decreased activity of LPL protein CTD PMID:8567968 7alpha-hydroxycholesterol decreases expression ISO RGD:70836 6480464 cholest-5-en-3 beta,7 alpha-diol results in decreased expression of LPL mRNA CTD PMID:8567968 8-bromo-3',5'-cyclic AMP increases expression EXP   6480464 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LPL mRNA CTD PMID:9032464 8-bromo-3',5'-cyclic AMP decreases activity ISO RGD:10876 6480464 8-Bromo Cyclic Adenosine Monophosphate results in decreased activity of LPL protein CTD PMID:9414485 9-cis-retinoic acid multiple interactions ISO RGD:70836 6480464 [alitretinoin co-treated with 22-hydroxycholesterol] results in increased expression of LPL mRNA; more ... CTD PMID:16142410 9-cis-retinoic acid increases expression ISO RGD:70836 6480464 alitretinoin results in increased expression of LPL mRNA CTD PMID:16142410 acetylcholine affects response to substance ISO RGD:70836 6480464 LPL protein affects the susceptibility to Acetylcholine CTD PMID:11786490 aldehydo-D-glucosamine 6-phosphate decreases expression ISO RGD:10876 6480464 glucosamine 6-phosphate results in decreased expression of LPL mRNA CTD PMID:19427183 all-trans-retinoic acid decreases expression ISO RGD:10876 6480464 Tretinoin results in decreased expression of LPL mRNA CTD PMID:16368784 all-trans-retinoic acid increases expression ISO RGD:70836 6480464 Tretinoin results in increased expression of LPL mRNA CTD PMID:21934132 all-trans-retinoic acid multiple interactions ISO RGD:10876 6480464 troglitazone inhibits the reaction [Tretinoin results in decreased expression of LPL mRNA] CTD PMID:16368784 alpha-hexachlorocyclohexane increases expression EXP   6480464 alpha-hexachlorocyclohexane results in increased expression of LPL mRNA CTD PMID:17785943 ammonium chloride affects expression EXP   6480464 Ammonium Chloride affects the expression of LPL mRNA CTD PMID:16483693 ATP affects response to substance ISO RGD:70836 6480464 LPL protein affects the susceptibility to Adenosine Triphosphate CTD PMID:11786490 benzbromarone increases expression ISO RGD:70836 6480464 Benzbromarone results in increased expression of LPL protein CTD PMID:18274627 benzene increases expression ISO RGD:10876 6480464 Benzene results in increased expression of LPL mRNA CTD PMID:15122651 PMID:15120971 benzene increases expression ISO RGD:10876 6480464 Benzene results in increased expression of LPL mRNA CTD PMID:15120971 PMID:15122651 benzo[a]pyrene decreases expression ISO RGD:70836 6480464 Benzo(a)pyrene results in decreased expression of LPL mRNA CTD PMID:20106945 benzo[a]pyrene increases expression ISO RGD:10876 6480464 Benzo(a)pyrene results in increased expression of LPL mRNA CTD PMID:21569818 benzo[a]pyrene multiple interactions ISO RGD:10876 6480464 [Benzo(a)pyrene co-treated with XPA gene mutant form co-treated with TRP53 gene mutant form] results in decreased expression of LPL mRNA CTD PMID:21715664 beta-carotene decreases expression ISO RGD:10876 6480464 beta Carotene results in decreased expression of LPL mRNA CTD PMID:21569430 bezafibrate increases activity ISO RGD:70836 6480464 Bezafibrate results in increased activity of LPL protein CTD PMID:8147947 more ... bezafibrate increases activity ISO RGD:70836 6480464 Bezafibrate results in increased activity of LPL protein CTD PMID:11164425 more ... bezafibrate increases activity EXP   6480464 Bezafibrate results in increased activity of LPL protein CTD PMID:9006809 PMID:2907502 bezafibrate increases activity ISO RGD:70836 6480464 Bezafibrate results in increased activity of LPL protein CTD PMID:8147947 more ... bezafibrate multiple interactions EXP   6480464 [Bezafibrate results in increased activity of LPL protein] which results in decreased abundance of Triglycerides CTD PMID:9006809 bezafibrate multiple interactions EXP   6480464 Bezafibrate inhibits the reaction [Lipopolysaccharides results in decreased expression of LPL mRNA] CTD PMID:17379010 bezafibrate increases activity EXP   6480464 Bezafibrate results in increased activity of LPL protein CTD PMID:2907502 PMID:9006809 bezafibrate multiple interactions ISO RGD:10876 6480464 PPARA protein affects the susceptibility to [Bezafibrate results in increased expression of LPL mRNA] CTD PMID:19124612 bezafibrate multiple interactions ISO RGD:10876 6480464 PPARA protein affects the reaction [Bezafibrate results in increased expression of LPL mRNA] CTD PMID:12782154 bezafibrate increases expression ISO RGD:10876 6480464 Bezafibrate results in increased expression of LPL mRNA CTD PMID:12782154 PMID:19124612 bezafibrate increases expression ISO RGD:10876 6480464 Bezafibrate results in increased expression of LPL mRNA CTD PMID:19124612 PMID:12782154 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:10876 6480464 Diethylhexyl Phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPL mRNA] CTD PMID:22197818 bis(2-ethylhexyl) phthalate increases expression ISO RGD:10876 6480464 Diethylhexyl Phthalate results in increased expression of LPL mRNA CTD PMID:19245819 bisphenol A multiple interactions ISO RGD:10876 6480464 bisphenol A inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPL mRNA] CTD PMID:22197818 bisphenol A increases expression ISO RGD:70836 6480464 bisphenol A results in increased expression of LPL mRNA CTD PMID:23090578 bisphenol A increases expression ISO RGD:10876 6480464 bisphenol A results in increased expression of LPL mRNA CTD PMID:15659569 bisphenol A multiple interactions ISO RGD:10876 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in increased expression of LPL mRNA] CTD PMID:15659569 bisphenol A multiple interactions ISO RGD:70836 6480464 [bisphenol A results in decreased expression of LPL mRNA] which affects the abundance of Triglycerides CTD PMID:22662114 bisphenol A decreases expression ISO RGD:70836 6480464 bisphenol A results in decreased expression of LPL mRNA CTD PMID:22662114 bisphenol A increases expression EXP   6480464 bisphenol A results in increased expression of LPL mRNA CTD PMID:20019905 cadmium dichloride multiple interactions ISO RGD:10876 6480464 [Methylnitronitrosoguanidine co-treated with Cadmium Chloride] results in decreased expression of LPL mRNA CTD PMID:19840844 cadmium dichloride decreases activity EXP   6480464 Cadmium Chloride results in decreased activity of LPL protein CTD PMID:18329778 cadmium sulfate multiple interactions ISO RGD:10876 6480464 cadmium sulfate affects the reaction [MTF1 affects the expression of LPL mRNA] CTD PMID:16221973 calcitriol decreases expression ISO RGD:10876 6480464 Calcitriol results in decreased expression of LPL mRNA CTD PMID:16368784 calcitriol multiple interactions ISO RGD:10876 6480464 troglitazone inhibits the reaction [Calcitriol results in decreased expression of LPL mRNA] CTD PMID:16368784 CGP 12177 increases expression EXP   6480464 CGP 12177 results in increased expression of LPL mRNA CTD PMID:9032464 chloroform increases expression EXP   6480464 Chloroform results in increased expression of LPL mRNA CTD PMID:17522070 chlorogenic acid multiple interactions EXP   6480464 Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; more ... CTD PMID:20696151 cholic acid multiple interactions EXP   6480464 [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of LPL mRNA CTD PMID:14684380 choline multiple interactions ISO RGD:10876 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of LPL mRNA CTD PMID:20938992 ciguatoxin CTX1B affects expression ISO RGD:10876 6480464 Ciguatoxins affects the expression of LPL mRNA CTD PMID:18353800 ciprofibrate increases expression ISO RGD:10876 6480464 ciprofibrate results in increased expression of LPL mRNA CTD PMID:12771043 ciprofibrate increases activity ISO RGD:70836 6480464 ciprofibrate results in increased activity of LPL protein CTD PMID:8593127 cisplatin decreases expression EXP   6480464 Cisplatin results in decreased expression of LPL mRNA CTD PMID:22023808 clofibrate increases expression EXP   6480464 Clofibrate results in increased expression of LPL mRNA CTD PMID:17522070 clofibrate increases expression EXP   6480464 Clofibrate results in increased expression of LPL mRNA CTD PMID:22008536 more ... clofibrate increases expression EXP   6480464 Clofibrate results in increased expression of LPL mRNA CTD PMID:12851107 more ... clofibrate increases activity ISO RGD:70836 6480464 Clofibrate results in increased activity of LPL protein CTD PMID:8593127 PMID:417937 clofibrate increases activity ISO RGD:70836 6480464 Clofibrate results in increased activity of LPL protein CTD PMID:417937 PMID:8593127 clofibrate multiple interactions ISO RGD:10876 6480464 [Clofibrate co-treated with Acetaminophen] affects the expression of LPL mRNA; more ... CTD PMID:17585979 clofibrate increases expression EXP   6480464 Clofibrate results in increased expression of LPL mRNA CTD PMID:12851107 more ... clofibrate increases expression ISO RGD:70836 6480464 Clofibrate results in increased expression of LPL protein CTD PMID:226883 clozapine decreases expression ISO RGD:10876 6480464 Clozapine results in decreased expression of LPL mRNA; more ... CTD PMID:19682446 clozapine increases expression ISO RGD:10876 6480464 Clozapine results in increased expression of LPL mRNA CTD PMID:17266109 cortisol multiple interactions ISO RGD:70836 6480464 Hydrocortisone results in decreased activity of and results in decreased expression of LPL protein CTD PMID:17549480 D-gluconic acid multiple interactions EXP   6480464 [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of LPL mRNA CTD PMID:16556975 D-glucose multiple interactions ISO RGD:70836 6480464 LPL protein promotes the reaction [Fatty Acids results in increased uptake of Glucose] CTD PMID:20628023 D-glucose decreases activity ISO RGD:10876 6480464 Glucose analog results in decreased activity of LPL protein CTD PMID:9414485 Delta(9)-tetrahydrocannabinol increases expression ISO RGD:70836 6480464 Tetrahydrocannabinol results in increased expression of LPL mRNA CTD PMID:18163980 Delta(9)-tetrahydrocannabinol decreases expression ISO RGD:10876 6480464 Tetrahydrocannabinol results in decreased expression of LPL mRNA CTD PMID:21955143 deoxycholic acid multiple interactions EXP   6480464 [gluconic acid co-treated with Deoxycholic Acid] results in increased expression of LPL mRNA CTD PMID:16556975 dexamethasone multiple interactions ISO RGD:70836 6480464 [rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LPL mRNA; more ... CTD PMID:20206132 dexamethasone multiple interactions ISO RGD:10876 6480464 Dexamethasone inhibits the reaction [Tetrachlorodibenzodioxin results in decreased activity of LPL protein] CTD PMID:9414485 dexamethasone multiple interactions ISO RGD:70836 6480464 [rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of LPL mRNA; more ... CTD PMID:23086663 dexamethasone multiple interactions ISO RGD:10876 6480464 [rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of LPL mRNA; more ... CTD PMID:23086663 dexamethasone multiple interactions ISO RGD:10876 6480464 bisphenol A inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPL mRNA]; more ... CTD PMID:22197818 dexamethasone multiple interactions ISO RGD:70836 6480464 [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPL mRNA; more ... CTD PMID:19186324 dexamethasone multiple interactions EXP   6480464 Progesterone inhibits the reaction [Dexamethasone results in increased activity of LPL protein] CTD PMID:12906939 dexamethasone increases activity EXP   6480464 Dexamethasone results in increased activity of LPL protein CTD PMID:12906939 dexamethasone multiple interactions ISO RGD:10876 6480464 [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of LPL mRNA; more ... CTD PMID:16054899 dexamethasone multiple interactions ISO RGD:10876 6480464 [Dexamethasone co-treated with INS1 protein] results in increased expression of LPL mRNA CTD PMID:9543393 diarsenic trioxide decreases expression ISO RGD:70836 6480464 arsenic trioxide results in decreased expression of LPL mRNA CTD PMID:19128835 diazoxide multiple interactions EXP   6480464 cirazoline promotes the reaction [Isoproterenol results in increased expression of LPL mRNA] CTD PMID:9032464 diazoxide decreases expression ISO RGD:10876 6480464 Isoproterenol results in decreased expression of LPL mRNA CTD PMID:21335049 diazoxide multiple interactions EXP   6480464 naringin inhibits the reaction [Isoproterenol results in decreased activity of LPL protein] CTD PMID:16906524 diazoxide increases expression EXP   6480464 Isoproterenol results in increased expression of LPL mRNA CTD PMID:9032464 diazoxide decreases activity EXP   6480464 Isoproterenol results in decreased activity of LPL protein CTD PMID:16906524 dichlorvos decreases activity EXP   6480464 Dichlorvos results in decreased activity of LPL protein CTD PMID:3196159 diethylstilbestrol increases expression ISO RGD:10876 6480464 Diethylstilbestrol results in increased expression of LPL mRNA CTD PMID:22710028 diethylstilbestrol multiple interactions ISO RGD:10876 6480464 [troglitazone co-treated with Diethylstilbestrol] results in increased expression of LPL protein CTD PMID:22710028 dimethylarsinic acid decreases expression ISO RGD:70836 6480464 Cacodylic Acid results in decreased expression of LPL mRNA CTD PMID:23221991 erythromycin estolate increases expression EXP   6480464 Erythromycin Estolate results in increased expression of LPL mRNA CTD PMID:17522070 ethanol decreases expression ISO RGD:10876 6480464 Ethanol results in decreased expression of LPL mRNA CTD PMID:22173916 ethanol increases expression ISO RGD:10876 6480464 Ethanol results in increased expression of LPL mRNA CTD PMID:21955143 ethanol multiple interactions ISO RGD:10876 6480464 rosiglitazone inhibits the reaction [Ethanol results in decreased expression of LPL mRNA] CTD PMID:22173916 fenofibrate increases expression ISO RGD:10876 6480464 Fenofibrate results in increased expression of LPL mRNA CTD PMID:11798191 fenofibrate increases activity ISO RGD:70836 6480464 Fenofibrate results in increased activity of LPL protein CTD PMID:8593127 folic acid multiple interactions ISO RGD:10876 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of LPL mRNA CTD PMID:20938992 fulvestrant multiple interactions ISO RGD:10876 6480464 fulvestrant inhibits the reaction [ESR2 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]]; more ... CTD PMID:17974624 fulvestrant decreases expression ISO RGD:10876 6480464 fulvestrant results in decreased expression of LPL mRNA CTD PMID:17974624 fumonisin B1 increases expression ISO RGD:10876 6480464 fumonisin B1 results in increased expression of LPL mRNA CTD PMID:16221962 gemfibrozil increases activity ISO RGD:70836 6480464 Gemfibrozil results in increased activity of LPL protein CTD PMID:8593127 gemfibrozil increases activity EXP   6480464 Gemfibrozil results in increased activity of LPL protein CTD PMID:9006809 gemfibrozil multiple interactions EXP   6480464 [Gemfibrozil results in increased activity of LPL protein] which results in decreased abundance of Triglycerides CTD PMID:9006809 genistein decreases activity ISO RGD:10876 6480464 Genistein results in decreased activity of LPL protein CTD PMID:9414485 glucose multiple interactions ISO RGD:70836 6480464 LPL protein promotes the reaction [Fatty Acids results in increased uptake of Glucose] CTD PMID:20628023 glucose decreases activity ISO RGD:10876 6480464 Glucose analog results in decreased activity of LPL protein CTD PMID:9414485 griseofulvin affects expression ISO RGD:10876 6480464 Griseofulvin affects the expression of LPL mRNA CTD PMID:12735108 heparin multiple interactions EXP   6480464 [etofibrate co-treated with Heparin] results in increased secretion of LPL protein CTD PMID:3179329 indinavir decreases activity ISO RGD:10876 6480464 Indinavir results in decreased activity of LPL protein CTD PMID:11786383 indinavir multiple interactions ISO RGD:10876 6480464 [Stavudine co-treated with Lamivudine co-treated with Indinavir] affects the expression of LPL mRNA; more ... CTD PMID:11741158 indinavir increases expression ISO RGD:10876 6480464 Indinavir results in increased expression of LPL mRNA CTD PMID:11741158 indole-3-methanol affects expression EXP   6480464 indole-3-carbinol affects the expression of LPL mRNA CTD PMID:21396975 indomethacin multiple interactions ISO RGD:10876 6480464 Indomethacin inhibits the reaction [APC gene mutant form results in decreased expression of LPL mRNA] CTD PMID:17546600 indomethacin multiple interactions ISO RGD:70836 6480464 [rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of LPL mRNA; more ... CTD PMID:23086663 isoprenaline multiple interactions EXP   6480464 cirazoline promotes the reaction [Isoproterenol results in increased expression of LPL mRNA] CTD PMID:9032464 isoprenaline decreases expression ISO RGD:10876 6480464 Isoproterenol results in decreased expression of LPL mRNA CTD PMID:21335049 isoprenaline increases expression EXP   6480464 Isoproterenol results in increased expression of LPL mRNA CTD PMID:9032464 isoprenaline multiple interactions EXP   6480464 naringin inhibits the reaction [Isoproterenol results in decreased activity of LPL protein] CTD PMID:16906524 isoprenaline decreases activity EXP   6480464 Isoproterenol results in decreased activity of LPL protein CTD PMID:16906524 L-methionine multiple interactions ISO RGD:10876 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of LPL mRNA CTD PMID:20938992 lamivudine decreases expression ISO RGD:10876 6480464 Lamivudine results in decreased expression of LPL mRNA CTD PMID:11741158 lamivudine multiple interactions ISO RGD:10876 6480464 [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LPL mRNA; more ... CTD PMID:11741158 lead diacetate increases expression ISO RGD:10876 6480464 lead acetate results in increased expression of LPL mRNA CTD PMID:21829687 lithocholic acid increases expression ISO RGD:10876 6480464 Lithocholic Acid results in increased expression of LPL mRNA CTD PMID:20359477 LY294002 multiple interactions ISO RGD:70836 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [LPL protein promotes the reaction [IFNG protein results in increased expression of GBP1 mRNA]]; more ... CTD PMID:15994321 LY294002 multiple interactions ISO RGD:10876 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in increased expression of LPL mRNA] CTD PMID:15659569 mangiferin multiple interactions ISO RGD:70836 6480464 L 663536 inhibits the reaction [mangiferin results in increased activity of LPL protein]; more ... CTD PMID:15975614 mangiferin increases activity ISO RGD:70836 6480464 mangiferin results in increased activity of LPL protein CTD PMID:15975614 mangiferin increases expression ISO RGD:70836 6480464 mangiferin results in increased expression of LPL mRNA CTD PMID:15975614 melatonin decreases expression ISO RGD:70836 6480464 Melatonin results in decreased expression of LPL mRNA CTD PMID:20738756 morphine increases expression ISO RGD:10876 6480464 Morphine results in increased expression of LPL mRNA CTD PMID:21955143 N-methyl-N'-nitro-N-nitrosoguanidine multiple interactions ISO RGD:10876 6480464 [Methylnitronitrosoguanidine co-treated with Okadaic Acid] results in decreased expression of LPL mRNA; more ... CTD PMID:19840844 N-nitrosodiethylamine increases expression ISO RGD:10876 6480464 Diethylnitrosamine results in increased expression of LPL mRNA CTD PMID:12771043 N-nitrosodiethylamine multiple interactions EXP   6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of LPL mRNA CTD PMID:18164116 naringin multiple interactions EXP   6480464 naringin inhibits the reaction [Isoproterenol results in decreased activity of LPL protein] CTD PMID:16906524 nevirapine increases expression ISO RGD:70836 6480464 Nevirapine results in increased expression of LPL mRNA CTD PMID:21619898 nicotinamide multiple interactions EXP   6480464 [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; more ... CTD PMID:20696151 ochratoxin A decreases expression ISO RGD:70836 6480464 ochratoxin A results in decreased expression of LPL CTD PMID:20590410 okadaic acid multiple interactions ISO RGD:10876 6480464 [Methylnitronitrosoguanidine co-treated with Okadaic Acid] results in decreased expression of LPL mRNA CTD PMID:19840844 paracetamol multiple interactions ISO RGD:10876 6480464 [Clofibrate co-treated with Acetaminophen] affects the expression of LPL mRNA; more ... CTD PMID:17585979 paracetamol decreases expression ISO RGD:10876 6480464 Acetaminophen results in decreased expression of LPL mRNA CTD PMID:15030884 paraquat decreases expression EXP   6480464 Paraquat results in decreased expression of LPL mRNA CTD PMID:17077588 perfluorooctane-1-sulfonic acid increases expression ISO RGD:10876 6480464 perfluorooctane sulfonic acid results in increased expression of LPL mRNA CTD PMID:21705711 perfluorooctane-1-sulfonic acid increases expression EXP   6480464 perfluorooctane sulfonic acid results in increased expression of LPL mRNA CTD PMID:18692542 perfluorooctanoic acid increases expression EXP   6480464 perfluorooctanoic acid results in increased expression of LPL mRNA CTD PMID:16221955 PMID:19162173 perfluorooctanoic acid increases expression EXP   6480464 perfluorooctanoic acid results in increased expression of LPL mRNA CTD PMID:19162173 PMID:16221955 phencyclidine increases expression ISO RGD:10876 6480464 Phencyclidine results in increased expression of LPL mRNA CTD PMID:17266109 phenobarbital multiple interactions ISO RGD:10876 6480464 NR1I3 protein affects the reaction [Phenobarbital results in increased expression of LPL mRNA] CTD PMID:19482888 phenobarbital affects expression ISO RGD:10876 6480464 Phenobarbital affects the expression of LPL mRNA CTD PMID:19136022 PMID:23091169 phenobarbital increases expression EXP   6480464 Phenobarbital results in increased expression of LPL mRNA CTD PMID:22008526 PMID:22008536 phenobarbital increases expression EXP   6480464 Phenobarbital results in increased expression of LPL mRNA CTD PMID:22008536 PMID:22008526 phenobarbital increases expression ISO RGD:10876 6480464 Phenobarbital results in increased expression of LPL mRNA CTD PMID:19482888 phenobarbital affects expression ISO RGD:10876 6480464 Phenobarbital affects the expression of LPL mRNA CTD PMID:19136022 phenylephrine affects response to substance ISO RGD:70836 6480464 LPL protein affects the susceptibility to Phenylephrine CTD PMID:11786490 phorbol 13-acetate 12-myristate increases expression ISO RGD:70836 6480464 Tetradecanoylphorbol Acetate results in increased expression of LPL protein CTD PMID:18435438 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:10876 6480464 [Methylnitronitrosoguanidine co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of LPL mRNA CTD PMID:19840844 pirinixic acid affects expression ISO RGD:10876 6480464 pirinixic acid affects the expression of LPL mRNA CTD PMID:19136022 pirinixic acid increases expression ISO RGD:10876 6480464 pirinixic acid results in increased expression of LPL mRNA CTD PMID:11798191 more ... pirinixic acid increases expression ISO RGD:10876 6480464 pirinixic acid results in increased expression of LPL mRNA CTD PMID:11798191 more ... pirinixic acid increases expression ISO RGD:10876 6480464 pirinixic acid results in increased expression of LPL mRNA CTD PMID:15375163 more ... pirinixic acid increases expression ISO RGD:10876 6480464 pirinixic acid results in increased expression of LPL mRNA CTD PMID:16357043 more ... pirinixic acid increases expression ISO RGD:10876 6480464 pirinixic acid results in increased expression of LPL mRNA CTD PMID:16306350 more ... pirinixic acid multiple interactions ISO RGD:10876 6480464 PPARA protein promotes the reaction [pirinixic acid results in increased expression of LPL mRNA] CTD PMID:20059764 PMID:17950772 pirinixic acid increases expression ISO RGD:10876 6480464 pirinixic acid results in increased expression of LPL mRNA CTD PMID:16306350 more ... pirinixic acid increases expression ISO RGD:10876 6480464 pirinixic acid results in increased expression of LPL mRNA CTD PMID:20059764 more ... pirinixic acid increases expression EXP   6480464 pirinixic acid results in increased expression of LPL mRNA CTD PMID:19162173 pirinixic acid multiple interactions ISO RGD:10876 6480464 PPARA protein promotes the reaction [pirinixic acid results in increased expression of LPL mRNA] CTD PMID:17950772 PMID:20059764 pirinixic acid increases expression ISO RGD:10876 6480464 pirinixic acid results in increased expression of LPL mRNA CTD PMID:11798191 more ... pirinixic acid multiple interactions ISO RGD:10876 6480464 PPARA protein affects the reaction [pirinixic acid results in increased expression of LPL mRNA] CTD PMID:16221962 pirinixic acid decreases expression ISO RGD:10876 6480464 pirinixic acid results in decreased expression of LPL mRNA CTD PMID:18445702 potassium chloride increases response to substance ISO RGD:70836 6480464 LPL protein results in increased susceptibility to Potassium Chloride CTD PMID:11786490 prazosin multiple interactions EXP   6480464 Prazosin inhibits the reaction [Norepinephrine results in increased expression of LPL mRNA] CTD PMID:9032464 pregnenolone 16alpha-carbonitrile decreases expression EXP   6480464 Pregnenolone Carbonitrile results in decreased expression of LPL mRNA CTD PMID:19162173 progesterone affects expression ISO RGD:10876 6480464 Progesterone affects the expression of LPL mRNA CTD PMID:17251523 progesterone multiple interactions EXP   6480464 Progesterone inhibits the reaction [Dexamethasone results in increased activity of LPL protein] CTD PMID:12906939 progesterone decreases expression ISO RGD:10876 6480464 Progesterone results in decreased expression of LPL mRNA CTD PMID:17974624 progesterone multiple interactions ISO RGD:10876 6480464 Progesterone inhibits the reaction [ESR2 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]]; more ... CTD PMID:17974624 propranolol multiple interactions EXP   6480464 Propranolol inhibits the reaction [Norepinephrine results in increased expression of LPL mRNA] CTD PMID:9032464 raloxifene multiple interactions ISO RGD:70836 6480464 [Raloxifene co-treated with ESR1 protein] results in increased expression of LPL mRNA CTD PMID:19059307 raloxifene increases expression ISO RGD:10876 6480464 Raloxifene results in increased expression of LPL mRNA CTD PMID:16643890 rel-(3R,5S)-fluvastatin multiple interactions ISO RGD:70836 6480464 [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; more ... CTD PMID:19773416 resveratrol decreases expression ISO RGD:10876 6480464 resveratrol metabolite results in decreased expression of LPL mRNA CTD PMID:22945685 resveratrol decreases expression ISO RGD:10876 6480464 resveratrol results in decreased expression of LPL mRNA CTD PMID:18555852 resveratrol decreases activity EXP   6480464 resveratrol results in decreased activity of LPL protein CTD PMID:21569266 resveratrol decreases expression ISO RGD:70836 6480464 resveratrol results in decreased expression of LPL mRNA CTD PMID:16901463 rosiglitazone multiple interactions ISO RGD:70836 6480464 [rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LPL mRNA; more ... CTD PMID:20206132 rosiglitazone increases expression ISO RGD:10876 6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:11916924 more ... rosiglitazone multiple interactions ISO RGD:10876 6480464 [rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of LPL mRNA; more ... CTD PMID:23086663 rosiglitazone multiple interactions ISO RGD:70836 6480464 [rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of LPL mRNA; more ... CTD PMID:23086663 rosiglitazone increases expression ISO RGD:10876 6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:11916924 more ... rosiglitazone increases expression EXP   6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:15887043 PMID:21515302 rosiglitazone increases expression ISO RGD:70836 6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:12814394 more ... rosiglitazone increases expression ISO RGD:70836 6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:15277403 more ... rosiglitazone increases expression ISO RGD:10876 6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:15997096 more ... rosiglitazone increases expression ISO RGD:10876 6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:11916924 more ... rosiglitazone increases expression ISO RGD:70836 6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:15277403 more ... rosiglitazone increases expression EXP   6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:15887043 rosiglitazone increases expression ISO RGD:10876 6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:12021203 more ... rosiglitazone multiple interactions ISO RGD:10876 6480464 rosiglitazone inhibits the reaction [Linoleic Acids, Conjugated results in decreased expression of LPL mRNA] CTD PMID:17322064 rosiglitazone increases expression ISO RGD:70836 6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:15619071 more ... rosiglitazone affects transport ISO RGD:70836 6480464 rosiglitazone affects the transport of LPL protein CTD PMID:16896939 rosiglitazone increases expression ISO RGD:10876 6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:12021203 PMID:15997096 rosiglitazone multiple interactions ISO RGD:10876 6480464 rosiglitazone inhibits the reaction [Ethanol results in decreased expression of LPL mRNA] CTD PMID:22173916 rosiglitazone affects expression ISO RGD:10876 6480464 rosiglitazone affects the expression of LPL protein CTD PMID:21347706 rosiglitazone multiple interactions ISO RGD:70836 6480464 rosiglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPL mRNA] CTD PMID:19186324 rosiglitazone increases expression ISO RGD:10876 6480464 rosiglitazone results in increased expression of LPL mRNA CTD PMID:15997096 PMID:12021203 rosiglitazone multiple interactions ISO RGD:10876 6480464 [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of LPL mRNA; more ... CTD PMID:16054899 rotenone decreases expression EXP   6480464 Rotenone results in decreased expression of LPL mRNA CTD PMID:19693701 saquinavir decreases activity ISO RGD:10876 6480464 Saquinavir results in decreased activity of LPL protein CTD PMID:11786383 saquinavir decreases expression ISO RGD:10876 6480464 Saquinavir results in decreased expression of LPL mRNA CTD PMID:11741158 simvastatin decreases expression EXP   6480464 Simvastatin results in decreased expression of LPL CTD PMID:19216230 simvastatin increases expression EXP   6480464 Simvastatin results in increased expression of LPL protein CTD PMID:2009092 stavudine multiple interactions ISO RGD:10876 6480464 [Stavudine co-treated with Lamivudine co-treated with Indinavir] affects the expression of LPL mRNA; more ... CTD PMID:11741158 streptozocin multiple interactions EXP   6480464 [Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein; more ... CTD PMID:20696151 tamoxifen affects expression ISO RGD:70836 6480464 Tamoxifen affects the expression of LPL mRNA CTD PMID:14699072 tamoxifen affects expression ISO RGD:10876 6480464 Tamoxifen affects the expression of LPL mRNA CTD PMID:20937368 PMID:17555576 tamoxifen decreases expression ISO RGD:70836 6480464 Tamoxifen results in decreased expression of LPL protein CTD PMID:3108557 tamoxifen affects expression ISO RGD:10876 6480464 Tamoxifen affects the expression of LPL mRNA CTD PMID:17555576 PMID:20937368 tamoxifen multiple interactions ISO RGD:70836 6480464 [Tamoxifen co-treated with ESR1 protein] results in increased expression of LPL mRNA CTD PMID:19059307 tert-butyl hydroperoxide decreases expression ISO RGD:70836 6480464 tert-Butylhydroperoxide results in decreased expression of LPL mRNA CTD PMID:15336504 tetrachloromethane affects expression ISO RGD:10876 6480464 Carbon Tetrachloride affects the expression of LPL mRNA CTD PMID:17484886 tetrachloromethane increases expression EXP   6480464 Carbon Tetrachloride results in increased expression of LPL mRNA CTD PMID:17522070 tetrachloromethane multiple interactions ISO RGD:10876 6480464 PLG gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of LPL mRNA] CTD PMID:16006527 tetracycline increases expression EXP   6480464 Tetracycline results in increased expression of LPL mRNA CTD PMID:17522070 tetrahydrocurcumin multiple interactions EXP   6480464 tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; more ... CTD PMID:20696151 theophylline increases expression ISO RGD:70836 6480464 Theophylline results in increased expression of LPL mRNA CTD PMID:16083514 trans-resveratrol decreases expression ISO RGD:10876 6480464 resveratrol metabolite results in decreased expression of LPL mRNA CTD PMID:22945685 trans-resveratrol decreases expression ISO RGD:10876 6480464 resveratrol results in decreased expression of LPL mRNA CTD PMID:18555852 trans-resveratrol decreases activity EXP   6480464 resveratrol results in decreased activity of LPL protein CTD PMID:21569266 trans-resveratrol decreases expression ISO RGD:70836 6480464 resveratrol results in decreased expression of LPL mRNA CTD PMID:16901463 tributylstannane multiple interactions ISO RGD:10876 6480464 tributyltin promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPL mRNA] CTD PMID:22197818 tributylstannane increases expression ISO RGD:10876 6480464 tributyltin results in increased expression of LPL mRNA CTD PMID:23322813 triclosan decreases expression ISO RGD:70836 6480464 Triclosan results in decreased expression of LPL mRNA CTD PMID:22726953 troglitazone multiple interactions ISO RGD:10876 6480464 troglitazone inhibits the reaction [Calcitriol results in decreased expression of LPL mRNA]; more ... CTD PMID:16368784 troglitazone increases expression ISO RGD:10876 6480464 troglitazone results in increased expression of LPL mRNA CTD PMID:10233209 more ... troglitazone multiple interactions ISO RGD:10876 6480464 [troglitazone co-treated with Diethylstilbestrol] results in increased expression of LPL protein CTD PMID:22710028 troglitazone decreases expression EXP   6480464 troglitazone results in decreased expression of LPL mRNA CTD PMID:21515302 troglitazone increases expression ISO RGD:10876 6480464 troglitazone results in increased expression of LPL mRNA CTD PMID:19122273 PMID:10233209 troglitazone increases expression ISO RGD:10876 6480464 troglitazone results in increased expression of LPL protein CTD PMID:10233209 troglitazone increases expression ISO RGD:10876 6480464 troglitazone results in increased expression of LPL mRNA CTD PMID:10233209 PMID:19122273 troglitazone multiple interactions ISO RGD:70836 6480464 [troglitazone results in increased expression of LPL protein] which results in increased metabolism of Lipids CTD PMID:10233209 troglitazone increases expression ISO RGD:70836 6480464 troglitazone results in increased expression of LPL protein CTD PMID:10233209 troglitazone increases expression ISO RGD:10876 6480464 troglitazone results in increased expression of LPL mRNA CTD PMID:19122273 undecane increases expression EXP   6480464 undecane results in increased expression of LPL protein CTD PMID:17337753 valsartan multiple interactions ISO RGD:10876 6480464 [valsartan co-treated with AGT protein] results in increased activity of LPL protein CTD PMID:18640387 valsartan increases activity ISO RGD:10876 6480464 valsartan results in increased activity of LPL protein CTD PMID:18640387 vancomycin increases expression ISO RGD:10876 6480464 Vancomycin results in increased expression of LPL mRNA CTD PMID:18930951 zidovudine decreases expression ISO RGD:70836 6480464 Zidovudine results in decreased expression of LPL mRNA CTD PMID:16894629 zidovudine affects expression ISO RGD:70836 6480464 Zidovudine affects the expression of LPL mRNA CTD PMID:20032539 zidovudine multiple interactions ISO RGD:10876 6480464 [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LPL mRNA; more ... CTD PMID:11741158 zidovudine decreases expression ISO RGD:10876 6480464 Zidovudine results in decreased expression of LPL mRNA CTD PMID:11741158 zinc atom affects expression EXP   6480464 Zinc affects the expression of LPL mRNA CTD PMID:17181878 zinc atom decreases expression ISO RGD:10876 6480464 Zinc deficiency results in decreased expression of LPL mRNA CTD PMID:20857495 zinc(0) affects expression EXP   6480464 Zinc affects the expression of LPL mRNA CTD PMID:17181878 zinc(0) decreases expression ISO RGD:10876 6480464 Zinc deficiency results in decreased expression of LPL mRNA CTD PMID:20857495 Gene Ontology Annotations Biological Process Term Qualifier Evidence With Reference Notes Source Original Reference(s) fatty acid biosynthetic process   ISO RGD:70836 1624291 PMID:182536 RGD PMID:182536 lipid catabolic process   IDA   1580532   RGD   positive regulation of cholesterol storage   ISO RGD:70836 1624291 PMID:12573449 RGD PMID:12573449 positive regulation of cholesterol storage   IEA Ensembl:ENSP00000309757 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 positive regulation of macrophage derived foam cell differentiation   ISO RGD:10876 1624291 UniProtKB:P35951 RGD MGI:MGI:1888585 PMID:10858435 positive regulation of macrophage derived foam cell differentiation   IEA Ensembl:ENSMUSP00000015712 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 positive regulation of sequestering of triglyceride   ISO RGD:70836 1624291 PMID:12573449 RGD PMID:12573449 positive regulation of sequestering of triglyceride   IEA Ensembl:ENSP00000309757 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 response to cold   IEP   7241069   RGD   response to drug   IEP   2313581 masoprocol RGD   triglyceride biosynthetic process   IMP   70246   RGD   triglyceride catabolic process   ISO RGD:10876 1624291 MGI:MGI:3043892|PMID:15178420 RGD MGI:MGI:3043892 PMID:15178420 triglyceride catabolic process   IEA Ensembl:ENSMUSP00000015712 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 triglyceride catabolic process   ISO RGD:70836 1624291 PMID:3973011 RGD PMID:3973011 triglyceride catabolic process   ISO RGD:70836 1624291 PMID:182536 RGD PMID:182536 triglyceride homeostasis   ISO RGD:70836 1624291 UniProtKB:P02655 RGD PMID:17018885 triglyceride homeostasis   IEA Ensembl:ENSP00000309757 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 very-low-density lipoprotein particle remodeling   ISO RGD:70836 1624291 PMID:3973011 RGD PMID:3973011 Cellular Component Term Qualifier Evidence With Reference Notes Source Original Reference(s) anchored to membrane   IEA UniProtKB-KW:KW-0336 1600115 GO_REF:0000037 UniProtKB GO_REF:0000037 cell surface   ISO RGD:10876 1624291 MGI:MGI:4820887|PMID:20620994 RGD MGI:MGI:4820887 PMID:20620994 cell surface   IEA Ensembl:ENSMUSP00000015712 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 chylomicron   IEA UniProtKB-KW:KW-0162 1600115 GO_REF:0000037 UniProtKB GO_REF:0000037 extracellular matrix   IDA   1580532   RGD   extracellular space   ISO RGD:10876 1624291 MGI:MGI:3043892|PMID:15178420 RGD MGI:MGI:3043892 PMID:15178420 extracellular space   ISO RGD:70836 1624291 PMID:12573449 RGD PMID:12573449 plasma membrane   IEA UniProtKB-SubCell:SL-0039 1600115 GO_REF:0000039 UniProtKB GO_REF:0000039 very-low-density lipoprotein particle   IEA UniProtKB-KW:KW-0850 1600115 GO_REF:0000037 UniProtKB GO_REF:0000037 Molecular Function Term Qualifier Evidence With Reference Notes Source Original Reference(s) apolipoprotein binding   IEA Ensembl:ENSP00000309757 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 apolipoprotein binding   ISO RGD:70836 1624291 UniProtKB:Q6Q788 RGD PMID:15178420 heparin binding   ISO RGD:70836 1624291 PMID:12573449 RGD PMID:12573449 heparin binding   IEA Ensembl:ENSP00000309757 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 lipoprotein lipase activity   IDA   70246   RGD   lipoprotein lipase activity   ISO RGD:70836 1624291 PMID:3973011 RGD PMID:3973011 lipoprotein lipase activity   ISO RGD:10876 1624291 MGI:MGI:58020|PMID:2563260 RGD MGI:MGI:58020 PMID:2563260 lipoprotein lipase activity   ISO RGD:10876 1624291 MGI:MGI:3695062|PMID:16166565 RGD MGI:MGI:3695062 PMID:16166565 lipoprotein lipase activity   IDA   1580532   RGD   protein binding   ISO RGD:10876 1624291 UniProtKB:Q3U3R4 RGD MGI:MGI:4422142 PMID:19783858 protein binding   ISO RGD:70836 1624291 UniProtKB:Q8IV16 RGD PMID:20124439 protein binding   ISO RGD:70836 1624291 UniProtKB:Q8IV16 RGD PMID:17997385 receptor binding   ISO RGD:70836 1624291 UniProtKB:Q99523 RGD PMID:10085125 receptor binding   IEA Ensembl:ENSP00000309757 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 triglyceride binding   IDA   1580532   RGD   triglyceride lipase activity   ISO RGD:10876 1624291 MGI:MGI:3043892|PMID:15178420 RGD MGI:MGI:3043892 PMID:15178420 triglyceride lipase activity   IEA Ensembl:ENSMUSP00000015712 1600115 GO_REF:0000019 ENSEMBL GO_REF:0000019 triglyceride lipase activity   ISO RGD:70836 1624291 PMID:12573449 RGD PMID:12573449 triglyceride lipase activity   ISO RGD:70836 1624291 PMID:182536 RGD PMID:182536 Molecular Pathway Annotations Term Qualifier Evidence With Reference Notes Source Original Reference(s) Alzheimer disease pathway   IEA RGD:3017 6907045   KEGG rno:05010 eicosanoid signaling pathway via peroxisome proliferator-activated receptor gamma   IEA RGD:3017 6907045   KEGG rno:03320 glycerolipid metabolic pathway   IEA RGD:3017 6907045   KEGG rno:00561 lipid metabolic pathway   ISS RGD:70836 1357916   RGD   lipoprotein metabolic pathway   ISS RGD:70836 1357916   RGD   External Database Links KEGG Pathway Alzheimer's disease Glycerolipid metabolism PPAR signaling pathway Disease Annotations Coronary Artery Disease  (ISS) Diabetes Mellitus, Experimental  (IEP) Diabetes Mellitus, Type 2  (ISS) Diabetic Nephropathies  (ISS) Glomerulosclerosis, Focal Segmental  (IEP) Hyperlipidemia, Familial Combined  (ISS) Hyperlipoproteinemia Type I  (ISS) Hypertension  (ISS) Hypertriglyceridemia  (IED,ISS) Insulin Resistance  (ISS) Kidney Failure, Chronic  (IEP) Lipid Metabolism, Inborn Errors  (ISS) Muscular Diseases  (ISS) Myocardial Infarction  (ISS) Obesity  (IEP,ISS) Gene-Chemical Interaction Annotations (3S,5R)-fluvastatin  (ISO) (R)-noradrenaline  (EXP) (S)-nicotine  (ISO) 1-naphthyl isothiocyanate  (EXP) 17alpha-ethynylestradiol  (EXP,ISO) 17beta-estradiol  (EXP,ISO) 17beta-hydroxy-5alpha-androstan-3-one  (ISO) 2,2',4,4',5,5'-hexachlorobiphenyl  (EXP) 2,2',5,5'-tetrachlorobiphenyl  (ISO) 2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO) 2-butoxyethanol  (ISO) 25-hydroxycholesterol  (ISO) 3,3',4,4',5-pentachlorobiphenyl  (EXP) 3,3',5-triiodo-L-thyronine  (EXP) 3-isobutyl-1-methyl-7H-xanthine  (ISO) 7,12-dimethyltetraphene  (EXP) 7alpha-hydroxycholesterol  (ISO) 8-bromo-3',5'-cyclic AMP  (EXP,ISO) 9-cis-retinoic acid  (ISO) acetylcholine  (ISO) aldehydo-D-glucosamine 6-phosphate  (ISO) all-trans-retinoic acid  (ISO) alpha-hexachlorocyclohexane  (EXP) ammonium chloride  (EXP) ATP  (ISO) benzbromarone  (ISO) benzene  (ISO) benzo[a]pyrene  (ISO) beta-carotene  (ISO) bezafibrate  (EXP,ISO) bis(2-ethylhexyl) phthalate  (ISO) bisphenol A  (EXP,ISO) cadmium dichloride  (EXP,ISO) cadmium sulfate  (ISO) calcitriol  (ISO) CGP 12177  (EXP) chloroform  (EXP) chlorogenic acid  (EXP) cholic acid  (EXP) choline  (ISO) ciguatoxin CTX1B  (ISO) ciprofibrate  (ISO) cisplatin  (EXP) clofibrate  (EXP,ISO) clozapine  (ISO) cortisol  (ISO) D-gluconic acid  (EXP) D-glucose  (ISO) Delta(9)-tetrahydrocannabinol  (ISO) deoxycholic acid  (EXP) dexamethasone  (EXP,ISO) diarsenic trioxide  (ISO) diazoxide  (EXP,ISO) dichlorvos  (EXP) diethylstilbestrol  (ISO) dimethylarsinic acid  (ISO) erythromycin estolate  (EXP) ethanol  (ISO) fenofibrate  (ISO) folic acid  (ISO) fulvestrant  (ISO) fumonisin B1  (ISO) gemfibrozil  (EXP,ISO) genistein  (ISO) glucose  (ISO) griseofulvin  (ISO) heparin  (EXP) indinavir  (ISO) indole-3-methanol  (EXP) indomethacin  (ISO) isoprenaline  (EXP,ISO) L-methionine  (ISO) lamivudine  (ISO) lead diacetate  (ISO) lithocholic acid  (ISO) LY294002  (ISO) mangiferin  (ISO) melatonin  (ISO) morphine  (ISO) N-methyl-N'-nitro-N-nitrosoguanidine  (ISO) N-nitrosodiethylamine  (EXP,ISO) naringin  (EXP) nevirapine  (ISO) nicotinamide  (EXP) ochratoxin A  (ISO) okadaic acid  (ISO) paracetamol  (ISO) paraquat  (EXP) perfluorooctane-1-sulfonic acid  (EXP,ISO) perfluorooctanoic acid  (EXP) phencyclidine  (ISO) phenobarbital  (EXP,ISO) phenylephrine  (ISO) phorbol 13-acetate 12-myristate  (ISO) pirinixic acid  (EXP,ISO) potassium chloride  (ISO) prazosin  (EXP) pregnenolone 16alpha-carbonitrile  (EXP) progesterone  (EXP,ISO) propranolol  (EXP) raloxifene  (ISO) rel-(3R,5S)-fluvastatin  (ISO) resveratrol  (EXP,ISO) rosiglitazone  (EXP,ISO) rotenone  (EXP) saquinavir  (ISO) simvastatin  (EXP) stavudine  (ISO) streptozocin  (EXP) tamoxifen  (ISO) tert-butyl hydroperoxide  (ISO) tetrachloromethane  (EXP,ISO) tetracycline  (EXP) tetrahydrocurcumin  (EXP) theophylline  (ISO) trans-resveratrol  (EXP,ISO) tributylstannane  (ISO) triclosan  (ISO) troglitazone  (EXP,ISO) undecane  (EXP) valsartan  (ISO) vancomycin  (ISO) zidovudine  (ISO) zinc atom  (EXP,ISO) zinc(0)  (EXP,ISO) Gene Ontology Annotations Biological Process fatty acid biosynthetic process  (ISO) lipid catabolic process  (IDA) positive regulation of cholesterol storage  (IEA,ISO) positive regulation of macrophage derived foam cell differentiation  (IEA,ISO) positive regulation of sequestering of triglyceride  (IEA,ISO) response to cold  (IEP) response to drug  (IEP) triglyceride biosynthetic process  (IMP) triglyceride catabolic process  (IEA,ISO) triglyceride homeostasis  (IEA,ISO) very-low-density lipoprotein particle remodeling  (ISO) Cellular Component anchored to membrane  (IEA) cell surface  (IEA,ISO) chylomicron  (IEA) extracellular matrix  (IDA) extracellular space  (ISO) plasma membrane  (IEA) very-low-density lipoprotein particle  (IEA) Molecular Function apolipoprotein binding  (IEA,ISO) heparin binding  (IEA,ISO) lipoprotein lipase activity  (IDA,ISO) protein binding  (ISO) receptor binding  (IEA,ISO) triglyceride binding  (IDA) triglyceride lipase activity  (IEA,ISO) Molecular Pathway Annotations Alzheimer disease pathway  (IEA) eicosanoid signaling pathway via peroxisome proliferator-activated receptor gamma  (IEA) glycerolipid metabolic pathway  (IEA) lipid metabolic pathway  (ISS) lipoprotein metabolic pathway  (ISS) External Database Links KEGG Pathway Alzheimer's disease Glycerolipid metabolism PPAR signaling pathway References - curated 1. Annuzzi G, etal., Nutr Metab Cardiovasc Dis. 2008 Oct;18(8):531-8. Epub 2008 Mar 5. 2. Blanco-Dolado L, etal., Int J Exp Diabetes Res 2002;3(1):61-8. 3. Chen P, etal., J Biomed Sci. 2005;12(4):651-8. Epub 2005 Nov 10. 4. Cheng Y and Hauton D, Biochim Biophys Acta. 2008 Oct;1781(10):618-26. doi: 10.1016/j.bbalip.2008.07.006. Epub 2008 Aug 5. 5. Cho YS, etal., Exp Mol Med. 2008 Oct 31;40(5):523-32. 6. Faustinella F, etal., J Biol Chem 1991 Aug 5;266(22):14418-24. 7. GOA data from the GO Consortium 8. Izar MC, etal., Atherosclerosis. 2009 May;204(1):165-70. Epub 2008 Aug 14. 9. KEGG 10. Kwitek AE, etal., Genome Res. 2004 Apr;14(4):750-7 11. Laplante M, etal., Diabetes 2003 Feb;52(2):291-9. 12. Levak-Frank S, etal., J Clin Invest 1995 Aug;96(2):976-86. 13. Ma W, etal., Wei Sheng Yan Jiu. 2007 May;36(3):320-2. 14. Mead JR, etal., J Mol Med 2002 Dec;80(12):753-69. Epub 2002 Oct 24. 15. MGD data from the GO Consortium 16. Mullick AE, etal., Arterioscler Thromb Vasc Biol 2002 Dec 1;22(12):2080-5. 17. NCBI rat LocusLink and RefSeq merged data July 26, 2002 18. Ng MC, etal., Clin Genet. 2006 Jul;70(1):20-8. 19. Niu YG and Evans RD, Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1106-16. Epub 2008 Sep 9. 20. Perron P, etal., J Endocrinol Invest. 2007 Jul-Aug;30(7):551-7. 21. Picard F, etal., Am J Physiol Endocrinol Metab 2002 Feb;282(2):E412-8. 22. Pipeline to import KEGG annotations from KEGG into RGD Pathway Ontology 23. RGD automated data pipeline 24. RGD automated import pipeline for gene-chemical interactions 25. RGD Automated Pipelines 26. Sato T, etal., Kidney Int. 2003 Nov;64(5):1780-6. 27. Scribner KA, etal., Metabolism. 2000 Sep;49(9):1106-10. 28. Strausberg RL, etal., Proc Natl Acad Sci U S A 2002 Dec 24;99(26):16899-903. Epub 2002 Dec 11. 29. Tentative Sequence Data IDs. TIGR Gene Index, Rat Data 30. Vaziri ND, etal., Clin Exp Nephrol. 2012 Apr;16(2):238-43. Epub 2011 Oct 19. 31. Wang H, etal., Diabetes. 2009 Jan;58(1):116-24. Epub 2008 Oct 24. 32. Wang XL, etal., Circulation. 1996 Apr 1;93(7):1339-45. 33. Wu G, etal., J Biol Chem. 2003 Apr 4;278(14):11925-30. Epub 2003 Jan 27. 34. Yamaguchi M, etal., Int J Obes Relat Metab Disord 2002 May;26(5):610-7. 35. Yu XH, etal., Biochem Biophys Res Commun. 2006 Mar 3;341(1):82-7. Epub 2006 Jan 9. References - uncurated PubMed 11809775   11882325   11896485   11897675   12815182   12967632   1339374   1485686   15328075   15489334   15670333   15681706   15887043   15947029   16807550   17088546   17170230   17244606   17259660   17451160   17628524   17709442   17890220   17942824   18583709   19088434   20497648   21147877   21646389   22226882   2233752   22870821 RGD Disease Portals Lpl has been annotated in the following RGD Disease Portals. Biological Process Cancer Pathways Biological Process Cardiovascular Diseases Cardiovascular Pathways Biological Process Diabetes Diseases Diabetes Pathways Immune and Inflammatory Diseases Immune and Inflammatory Pathways Neurological Diseases Neurological Pathways Biological Process Obesity Diseases Obesity Pathways Respiratory Pathways Genomics Comparative Map Data Lpl   (Rattus norvegicus) Map Chr Position Strand Source Rat Cytogenetic Map 16 p14   NCBI RGSC Genome Assembly v5.0 16 22,432,084 - 22,455,884 - NCBI RGSC Genome Assembly v3.4 16 22,533,105 - 22,556,905 - NCBI Rat Celera Assembly 16 20,988,473 - 21,012,282 - NCBI Genome Assembly 3.1 16 22,532,512 - 22,556,890 - NCBI RH 3.4 16 252.82   RGD LPL   (Homo sapiens) Map Chr Position Strand Source Human Alternate Assembly CHM1_1 8 20,048,566 - 20,076,750 + NCBI Human Genome Assembly HuRef 8 18,336,820 - 18,365,002 + NCBI Human Genome Assembly GRCh37 8 19,796,582 - 19,824,770 + NCBI Human Genome Assembly Build 36 8 19,840,862 - 19,869,050 + NCBI Human Cytogenetic Map 8 p22   NCBI Human Genome Assembly 8 19,841,057 - 19,869,049   NCBI Lpl   (Mus musculus) Map Chr Position Strand Source Mouse Genome Assembly GRCm38 8 68,880,555 - 68,906,932 + NCBI Mouse cM Map 8 33.88   NCBI Mouse Celera Assembly 8 71,423,790 - 71,450,108 + NCBI Mouse Genome Assembly Build 37 8 71,404,454 - 71,430,831 + NCBI Mouse Genome Assembly Build 36.1 8 71,404,454 - 71,430,831 + NCBI Mouse Cytogenetic Map 8 B3.3   NCBI Position Markers RH94806   Map Chr Position Strand Source Rat Cytogenetic Map 16 p14   UniSTS RGSC Genome Assembly v5.0 16 22,432,915 - 22,433,211   UniSTS RGSC Genome Assembly v3.4 16 22,533,936 - 22,534,232   UniSTS Rat Celera Assembly 16 20,989,304 - 20,989,600   UniSTS RH 3.4 16 252.82   UniSTS RH94543   Map Chr Position Strand Source Rat Cytogenetic Map 16 p14   UniSTS RGSC Genome Assembly v5.0 16 22,432,199 - 22,432,378   UniSTS RGSC Genome Assembly v3.4 16 22,533,220 - 22,533,399   UniSTS Rat Celera Assembly 16 20,988,588 - 20,988,767   UniSTS QTLs in Region (RGSC Genome Assembly v3.4) The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer RGD ID Symbol Name LOD P Value Trait Sub Trait Chr Start Stop Species 1600369 Hcas8 Hepatocarcinoma susceptibility QTL 8 Liver tumor susceptibility nodule number 16 1 24132402 Rat 631830 Alc7 Alcohol consumption QTL 7 2.9 Consumption level alcohol preference 16 1 26804456 Rat 634355 Rends4 Renal damage susceptibility QTL 4 .05 Renal histology renal lesion severity 16 1 26804456 Rat 1582235 Insul8 Insulin level QTL 8 3.3 .0063 Insulin level 16 1 26804456 Rat 2302380 Slep6 Serum leptin concentration QTL 6 3.36 Hormone level leptin 16 1 32464321 Rat 2307172 Activ4 Activity QTL 4 3.71 .00023 Activity level Locomotor activity 16 1 33735317 Rat 1354584 Despr6 Despair related QTL 6 .0067 Activity level immobility level 16 1 40096603 Rat 2303566 Bw90 Body weight QTL 90 2 Body weight 16 1 40096603 Rat 631561 Hcuc2 Hepatic copper content QTL 2 2.8 Copper level hepatic 16 1 40096622 Rat 6903319 Bw114 Body weight QTL 114 2.7 .0037 Body weight 16 172013 45172013 Rat 1600378 Arunc4 Aerobic running capacity QTL 4 .03 Aerobic running capacity best distance run to exhaustion 16 350121 85734479 Rat 2293343 Glom16 Glomerulus QTL 16 9.1 Renal pathology glomerulus inflammation 16 819225 49333382 Rat 2312660 Bw95 Body weight QTL 95 .05 Body weight adiposity index 16 819225 63306215 Rat 2312663 Slep9 Serum leptin concentration QTL 9 .001 Hormone level leptin 16 819225 63306215 Rat 2312666 Insul16 Insulin level QTL 16 .01 Insulin level serum 16 819225 63306215 Rat 2312669 Stl23 Serum triglyceride level QTL 23 .01 Lipid level triglyceride 16 819225 63306215 Rat 1354625 Despr7 Despair related QTL 7 .016 Activity level immobility and climbing levels 16 1632183 46632183 Rat 1300133 Rf24 Renal function QTL 24 3.64 Renal function salt-loaded creatinine clearance 16 3464719 22979073 Rat 2306902 Bp339 Blood pressure QTL 339 .01 Blood pressure salt-loaded systolic 16 3464719 46137590 Rat 70183 BpQTLcluster13 Blood pressure QTL cluster 13 3.325 Blood pressure 16 4304396 46137590 Rat 61338 Bp23 Blood pressure QTL 23 4.3 Blood pressure salt-loaded systolic 16 4304396 49304396 Rat 737819 Hcas4 Hepatocarcinoma susceptibility QTL 4 4.43 Liver tumor susceptibility nodule number 16 4304396 50266190 Rat 61405 Niddm6 Non-insulin dependent diabetes mellitus QTL 6 3.66 .001 Glucose level 16 4304396 52304351 Rat 737826 Alc11 Alcohol consumption QTL 11 3.2 Consumption level alcohol preference 16 4304396 64081533 Rat 1357403 Slep4 Serum leptin concentration QTL 4 3.91 Hormone level leptin 16 9964433 30560825 Rat 631517 Scl9 Serum cholesterol level QTL 9 3.3 Lipid level cholesterol 16 16194598 22671959 Rat 70205 Gcr3 Gastric cancer resistance QTL 3 2.2 Gastric tumor resistance tumor invasions depth 16 18121291 70196694 Rat 70215 Niddm29 Non-insulin dependent diabetes mellitus QTL 29 3.54 Glucose level postprandial 16 19510772 80047126 Rat Sequence Nucleotide Sequences Nucleotide RefSeqs NM_012598 (Get FASTA) Search GEO for Microarray Profiles GenBank Nucleotide AABR06086982 (Get FASTA) Search GEO for Microarray Profiles   AAHX01086920 (Get FASTA) Search GEO for Microarray Profiles   BC081836 (Get FASTA) Search GEO for Microarray Profiles   CH474045 (Get FASTA) Search GEO for Microarray Profiles   CS417880 (Get FASTA) Search GEO for Microarray Profiles   L03294 (Get FASTA) Search GEO for Microarray Profiles Reference Sequences RefSeq Acc Id: NM_012598 RefSeq Status: PROVISIONAL Type: CODING Protein Acc Id: NP_036730 Peptide Label: precursor Position: Map Chr Position Strand Source RGSC Genome Assembly v5.0 16 22,432,084 - 22,455,884 - NCBI RGSC Genome Assembly v3.4 16 22,533,105 - 22,556,905 - RGD Rat Celera Assembly 16 20,988,473 - 21,012,282 - RGD Protein Sequences Protein RefSeqs NP_036730 (Get FASTA) GenBank Protein AAA41534 (Get FASTA)   AAH81836 (Get FASTA)   CAL48775 (Get FASTA)   EDL75930 (Get FASTA)   EDL75931 (Get FASTA)   Q06000 (Get FASTA) Strain Variation Strain Sequence Variants ACI/Eur (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 ACI/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) BN-Lx (ICL) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Imperial College London (Dr Timothy Aitman) Platform: SOLID Secondary Analysis: BWA, GATK, Samtools Breeder: Academy of Sciences of the Czech Republic (Dr.Michal Pravenec) Grant Information: MC-A654-5QB00 BN-Lx (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: Academy of Sciences of the Czech Republic (Dr.Michal Pravenec) Grant Information: EURATRANS (HEALTH-F4-2010-241504) BN/NHsdMcwi (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: Medical College of Wisconsin Grant Information: EURATRANS (HEALTH-F4-2010-241504) BN/SsN (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) Buf/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) COP/Crl (MCW & UW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Univiersity of Wisconsin (Jim Shull) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v2.3-5 Breeder: Charles River Grant Information: NIH (CA77876) F344/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) FHH/EurMcwi (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 FHH/EurMcwi (MDC) Visual CSV TAB Printer Sequenced By: Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: Illumina/Solexa, Genome Analyzer II Secondary Analysis: CASAVA Software v1.7 Breeder: Medical College of Wisconsin Grant Information: EURATRANS (HEALTH-F4-2010-241504) FHL/EurMcwi (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 GH/OmrMcwi (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v2.3-5 LE/Stm (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: Dr. Tadao Serikawa, Kyoto Japan. Grant Information: EURATRANS (HEALTH-F4-2010-241504) M520/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) MR/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) SHR/Olalpcv (ICL) Visual CSV TAB Printer Sequenced By: Imperial College London (Dr Timothy Aitman) University of British Columbia (Dr. Steven Jones) Platform: Illumina Hi-seq 2000 and GAII Secondary Analysis: BWA, GATK Breeder: Institute of Physiology, Academy of Sciences of the Czech Republic, Prague Grant Information: LSHG-CT-2005-019015, HEALTH-F4-2010-241504 SHR/Olalpcv (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Imperial College London (Dr Timothy Aitman) Platform: Illumina Secondary Analysis: GATK Grant Information: EURATRANS (HEALTH-F4-2010-241504) SHRSP/Gcrc (MDC) Visual CSV TAB Printer Sequenced By: Max Delbruch Center for Molecular Medicine (Dr. Norbert Huebner) Platform: Illumina/Solexa, Genome Analyzer II Secondary Analysis: CASAVA Software v1.7 Breeder: University of Glasgow, Anna Dominiczak Grant Information: EURATRANS (HEALTH-F4-2010-241504) SR/JrHsd (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 Breeder: Harlan SS/JrHsdMcwi (MCW) Visual CSV TAB Printer Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob) Platform: Illumina HiSeq 2000 Secondary Analysis: BWA v0.5.9-r16 and GATK v1.3-14 Grant Information: R01 HL089930 SS/JrHsdMcwi (MDC) Visual CSV TAB Printer Sequenced By: Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: Illumina/Solexa, Genome Analyzer II Secondary Analysis: CASAVA Software v1.7 Breeder: Medical College of Wisconsin Grant Information: EURATRANS (HEALTH-F4-2010-241504) WKY/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) WN/N (KNAW) Visual CSV TAB Printer Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen) Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner) Platform: SOLID Secondary Analysis: SAP42 (Developed at RNAAS) Breeder: National Institutes of Health Grant Information: EURATRANS (HEALTH-F4-2010-241504) Additional Information External Database Links Database Acc Id Source(s) Ensembl Genes ENSRNOG00000012181 ENTREZGENE, UniProtKB/Swiss-Prot Ensembl Protein ENSRNOP00000016543 ENTREZGENE, UniProtKB/Swiss-Prot Ensembl Transcript ENSRNOT00000016543 ENTREZGENE, UniProtKB/Swiss-Prot Entrez Gene 24539 ENTREZGENE Gene3D-CATH Lipase_LipOase UniProtKB/Swiss-Prot Germonline ENSRNOG00000012181 UniProtKB/Swiss-Prot HomoloGene Group ID 200 ENTREZGENE IMAGE_CLONE IMAGE:7106121 IMAGE-MGC_LOAD InterPro Lipase UniProtKB/Swiss-Prot   Lipase_LipOase UniProtKB/Swiss-Prot   Lipase_N UniProtKB/Swiss-Prot   Lipo_Lipase UniProtKB/Swiss-Prot   LipOase_LH2 UniProtKB/Swiss-Prot   Lipoprotein_lipase_LIPH UniProtKB/Swiss-Prot IPI IPI00189471 UniProtKB/Swiss-Prot KEGG Report rno:24539 ENTREZGENE, UniProtKB/Swiss-Prot MGC_CLONE MGC:93586 IMAGE-MGC_LOAD PANTHER Lipase UniProtKB/Swiss-Prot   Lipase_lipo UniProtKB/Swiss-Prot Pfam Lipase UniProtKB/Swiss-Prot   PLAT UniProtKB/Swiss-Prot PharmGKB LPL RGD PIRSF Lipoprotein_lipase_LIPH UniProtKB/Swiss-Prot PRINTS LIPOLIPASE UniProtKB/Swiss-Prot   TAGLIPASE UniProtKB/Swiss-Prot PROSITE LIPASE_SER UniProtKB/Swiss-Prot   PLAT UniProtKB/Swiss-Prot SMART LH2 UniProtKB/Swiss-Prot Superfamily-SCOP Lipase_LipOase UniProtKB/Swiss-Prot TIGR TC204043 TIGRFAMs lipo_lipase UniProtKB/Swiss-Prot UniGene Rn.3834 ENTREZGENE UniProt LIPL_RAT UniProtKB/Swiss-Prot Nomenclature History Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status 2002-06-10 Lpl  Lipoprotein lipase      Symbol and Name status set to approved 1490 APPROVED RGD Curation Notes Note Type Note Reference gene_disease upregulated in hyperinsulinemia 70246 gene_function hydrolyzes circulating plasma triglycerides 70246 gene_process involved in diet-induced insulin resistance 70246 gene_regulation expression is decreased by insulin deficiency 729358

More on Lpl Entrez Gene Ensembl Gene Genome Browser NCBI Map Viewer Vista Vista + UCSC RGD Object Information RGD ID: 3017 Created: 2000-05-25 Species: Rattus norvegicus Last Modified: 2013-04-16 Status: ACTIVE